Canadian evidence-based guidelines support the use of a cholinesterase inhibitor or memantine, or both drugs for the management of patients with severe Alzheimer's disease.
The U.S. National Cancer Institute recently announced it's sponsoring a study focused on the cold and flu fighting potential of COLD-Fx in leukemia patients.